Becker's Healthcare September 24, 2024
Sen. Bernie Sanders highlighted a potential shift in the pricing of Ozempic during a Senate Health, Education, Labor and Pensions Committee hearing Sept. 24, during which three major pharmacy benefit managers said they would increase coverage if Novo Nordisk lowered the drug’s list price.
Here are five key takeaways:
- During the hearing, Novo Nordisk CEO Lars Fruergaard Jørgensen attributed the high prices of drugs such as Ozempic and Wegovy to PBMs, arguing that “a high list price is more likely to lead to more access to patients,” NBC News reported Sept. 24.
- Mr. Jørgensen also noted that when setting a list price for a medication, the company has to take into account the rebates it has...
Today's Sponsors
Today's Sponsor